Aliyah Pabani

1.5k total citations · 2 hit papers
32 papers, 814 citations indexed

About

Aliyah Pabani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Aliyah Pabani has authored 32 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Aliyah Pabani's work include Lung Cancer Treatments and Mutations (20 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (9 papers). Aliyah Pabani is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (9 papers). Aliyah Pabani collaborates with scholars based in Canada, United States and Denmark. Aliyah Pabani's co-authors include Justin F. Gainor, Naiyer A. Rizvi, Michael Lanuti, Codruța Chiuzan, Catherine A. Shu, Mark M. Awad, Simon K. Cheng, Joshua Sonett, Anjali Saqi and Mark Stoopler and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Aliyah Pabani

27 papers receiving 807 citations

Hit Papers

Neoadjuvant atezolizumab and chemotherapy in patients wit... 2020 2026 2022 2024 2020 2024 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
    2020 425 citations Catherine A. Shu, Justin F. Gainor et al. The Lancet Oncology profile →
  2. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    2024 60 citations Sarah Cook, Daniel E. Meyers et al. JAMA Network Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aliyah Pabani Canada 13 629 533 86 82 80 32 814
Hayato Kawachi Japan 12 549 0.9× 435 0.8× 83 1.0× 88 1.1× 92 1.1× 35 711
Iveta Kudaba Latvia 14 635 1.0× 490 0.9× 97 1.1× 75 0.9× 61 0.8× 24 750
Ayako Shiono Japan 15 605 1.0× 389 0.7× 44 0.5× 185 2.3× 76 0.9× 59 783
Junxun Ma China 18 596 0.9× 373 0.7× 95 1.1× 135 1.6× 124 1.6× 45 796
Guoqiang Wang China 9 455 0.7× 227 0.4× 62 0.7× 101 1.2× 89 1.1× 24 561
Giulia Mazzaschi Italy 11 444 0.7× 254 0.5× 50 0.6× 166 2.0× 130 1.6× 54 634
Audrey Simonaggio France 10 445 0.7× 278 0.5× 48 0.6× 82 1.0× 104 1.3× 23 567
Tsukihisa Yoshida Japan 14 377 0.6× 456 0.9× 73 0.8× 24 0.3× 122 1.5× 34 650
Joshua E. Reuss United States 13 370 0.6× 257 0.5× 51 0.6× 51 0.6× 124 1.6× 54 521
Yosuke Kawashima Japan 11 605 1.0× 339 0.6× 53 0.6× 112 1.4× 77 1.0× 41 721

Countries citing papers authored by Aliyah Pabani

Since Specialization
Citations

This map shows the geographic impact of Aliyah Pabani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aliyah Pabani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aliyah Pabani more than expected).

Fields of papers citing papers by Aliyah Pabani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aliyah Pabani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aliyah Pabani. The network helps show where Aliyah Pabani may publish in the future.

Co-authorship network of co-authors of Aliyah Pabani

This figure shows the co-authorship network connecting the top 25 collaborators of Aliyah Pabani. A scholar is included among the top collaborators of Aliyah Pabani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aliyah Pabani. Aliyah Pabani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sinnarajah, Aynharan, Sadia Ahmed, Desirée Hao, et al.. (2025). Patient-Rated Acceptability of Automatic Palliative Care Referral: A Prospective Cohort Study. Journal of Pain and Symptom Management. 69(5). 465–472.
2.
3.
Johnson, Sonali, Alessandro Crestani, Haris Majeed, et al.. (2025). Antimicrobial resistance in patients with haematological malignancies: a scoping review. The Lancet Oncology. 26(5). e242–e252. 1 indexed citations
4.
Cook, Sarah, Daniel E. Meyers, Igor Stukalin, et al.. (2024). Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Network Open. 7(1). e2352302–e2352302. 60 indexed citations breakdown →
5.
Pabani, Aliyah, Mitchell S. von Itzstein, Run Fan, et al.. (2024). Use of artificial intelligence chatbots in clinical management of immune-related adverse events. Journal for ImmunoTherapy of Cancer. 12(5). e008599–e008599. 14 indexed citations
6.
Ahmed, Sadia, Jessica Simon, Patricia Biondo, et al.. (2024). Acceptability of automatic referrals to supportive and palliative care by patients living with advanced lung cancer: qualitative interviews and a co-design process. Research Involvement and Engagement. 10(1). 36–36. 2 indexed citations
7.
8.
Navani, Vishal, Daniel E. Meyers, Yibing Ruan, et al.. (2023). Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade. Clinical Lung Cancer. 24(3). e152–e159. 2 indexed citations
9.
Wilson, Brooke E., Rouhi Fazelzad, Aliyah Pabani, et al.. (2023). Scoping review protocol on the impact of antimicrobial resistance on cancer management and outcomes. BMJ Open. 13(2). e068122–e068122. 14 indexed citations
10.
Pabani, Aliyah, et al.. (2023). Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC. JTO Clinical and Research Reports. 4(3). 100460–100460. 7 indexed citations
11.
Pabani, Aliyah & Justin F. Gainor. (2023). Facts and Hopes: Immunocytokines for Cancer Immunotherapy. Clinical Cancer Research. 29(19). 3841–3849. 13 indexed citations
12.
13.
Meyers, Daniel E., Igor Stukalin, Vishal Navani, et al.. (2023). Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors. JTO Clinical and Research Reports. 4(4). 100482–100482. 14 indexed citations
14.
Wheatley‐Price, Paul, Vishal Navani, Aliyah Pabani, et al.. (2023). MA16.06 Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study. Journal of Thoracic Oncology. 18(11). S159–S159. 2 indexed citations
15.
Ghosh, Sunita, Daniel E. Meyers, Igor Stukalin, et al.. (2023). Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study. Current Oncology. 30(12). 10396–10407. 4 indexed citations
16.
17.
Gan, Chun Loo, Igor Stukalin, Daniel E. Meyers, et al.. (2021). Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer. 151. 115–125. 32 indexed citations
18.
Chen, Gan, Daniel E. Meyers, Igor Stukalin, et al.. (2020). 425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents. Annals of Oncology. 31. S1408–S1408. 2 indexed citations
19.
Shu, Catherine A., Justin F. Gainor, Mark M. Awad, et al.. (2020). Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. The Lancet Oncology. 21(6). 786–795. 425 indexed citations breakdown →
20.
Camidge, D. Ross, et al.. (2019). Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib. Journal of Thoracic Oncology. 14(9). 1547–1555. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hayato Kawachi Breakdown of academic impact, for papers by Iveta Kudaba Breakdown of academic impact, for papers by Ayako Shiono Breakdown of academic impact, for papers by Junxun Ma Breakdown of academic impact, for papers by Guoqiang Wang Breakdown of academic impact, for papers by Giulia Mazzaschi Breakdown of academic impact, for papers by Audrey Simonaggio Breakdown of academic impact, for papers by Tsukihisa Yoshida Breakdown of academic impact, for papers by Joshua E. Reuss Breakdown of academic impact, for papers by Yosuke Kawashima
Rankless by CCL
2026